[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kate Farms Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100610995","trial-of-partial-enteral-nutrition-with-dairy-free-diet-in-eosinophilic-esophagitis-100610995",false,"NCT07234825","Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis","Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis Induction of Remission","Inclusion Criteria:\n\n* Pediatric patients 1 year to 21 of age presenting with chronic symptoms of dysphagia, odynophagia, vomiting or heartburn, chronic abdominal pain, weight loss, picky eating, to outpatient gastroenterology clinic and are planning to undergo EGD for evaluation.\n\nExclusion Criteria:\n\n* Non-English-Speaking Subjects, adults unable to consent, wards of the state, pregnant women, and prisoners will be excluded from the study.\n* Patients with autoimmune conditions such as inflammatory bowel disease. Patients with prior esophageal or intestinal surgeries.\n* Patients with history of eating disorders or ARFID.\n* Patients with fistulizing or fibrotic disease on baseline EGD.\n* Patients who have received proton pump inhibitory therapy in the past month.","ALL","1 Year","21 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut microbiota, and environmental toxin exposures.",[27],"Eosinophilic Esophagitis (EoE)","RECRUITING","2026-04-13",{"date":31,"type":32},"2026-04-16","ACTUAL",{"date":34,"type":32},"2026-03-18",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Kate Farms Inc","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100610755","growth-and-tolerance-of-plant-based-enteral-formulas-in-children-ages-12-17-months-100610755","NCT07231705","Growth and Tolerance of Plant-based Enteral Formulas in Children Ages 12-17 Months.","Growth and Enteral Tolerance of Plant-Based Enteral Formulas: A Prospective Study","Inclusion Criteria:\n\n* Children, male or female, aged 12 through 17 months (for premature infants, we will use corrected age)\n* Children with a weight-for-length z score between ≥ -1.5 at enrolment\n* Children obtaining via formula feeding ≥ 80% of their total energy intake at enrolment and expected to continue to require such formula intake for the next 24 weeks\n* Children from families who are willing and able to comply with the requirements of the protocol\n* Written informed consent from the parent or legal guardian\n* Parent\u002Fcaregiver or legal guardian must be able to read, write, and understand English\n\nExclusion Criteria:\n\n* Children with known or suspected complex gastrointestinal anomalies or dysfunction, hepatic or renal dysfunction, or inherited metabolic disorders, suspected or diagnosed conditions associated with malabsorption (e.g. cystic fibrosis) (Note: For hepatic dysfunction, a conjugated bilirubin \\>2.0 mg\u002FdL and for renal dysfunction child should not meet any of the Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease (pRIFLE) criteria for renal disease (estimated creatinine clearance decreased by 25% by the Schwartz formula or urine output \\\u003C0.5 mL\u002Fkg per hour over the previous 8 or more hours) or has chronic medical renal disease. We will not obtain labs to exclude children. If children are noted to have liver disease or renal disease in their chart, we will look at their labs to ensure that they do not meet exclusion criteria).\n* Children with tracheostomy and\u002For inspired oxygen via nasal cannula or children receiving diuretics.\n* Children with known or suspected genetic and\u002For metabolic inborn errors of metabolism conditions known to interfere with growth or body dysmorphology that can interfere with obtaining standard anthropometric measurements (weight, length, head circumference, and arm circumference)\n* At study entry, children expected to consume on average more than 20% of their energy intake from non-formula sources of nutrition: solids, expressed breast milk and \u002For parenteral nutrition.\n* Child requiring or expected to have an energy requirement \\\u003C 80 kcal\u002Fkg per day - Breastfeeding child (who is feeding at the breast \\> 2 times per day)\n* Child likely to undergo major surgery during the duration of the study\n* Child with a nasogastric tube that is unlikely to get a gastrostomy tube during the duration of the study\n* Principal Investigator's uncertainty about the willingness or ability of the parent\u002Fcaregiver to comply with the protocol requirements\n* Children whose parent is younger than the legal age of consent\n* Children with known allergy to pea protein or soy or peanuts.\n* Children with a parent or a sibling with a known allergy to pea protein or soy or peanuts.","12 Months","17 Months",{"count":51,"type":21},40,[24],"The purpose of this prospective study is to evaluate the growth and enteral tolerance of two pea protein-based formulas from Kate Farms in children aged 12 to 17 months who are expected to meet most of their nutritional needs through formula. It is hypothesized that the Pediatric Standard 1.2 and Pediatric Peptide 1.0 formulas will support healthy growth in children between 1 and 2 years of age. The study will assess the impact of these formulas on growth, tolerance, body composition, micronutrient levels, and gut microbiome health in tube-fed children. Formula will be provided for 24 weeks.",[55],"Formula Dependent Children 1 to 2 Years of Age",{"date":57,"type":32},"2026-04-14",{"date":59,"type":32},"2026-03-13",{"date":61,"type":21},"2028-03-31",{"name":38,"class":39},""]